Studies are now starting to evaluate the role of the gut microbiome in anti‐PD‐1 immunotherapy,101, 102 including the first clinical study focusing on PD‐1 checkpoint inhibitor response in metastatic melanoma. The gene discussed is PDCD1; the disease is metastatic melanoma.